HER2 amplification as a potential mechanism of acquired resistance to afatinib in an advanced non-small-cell lung cancer patient

Lung Cancer. 2021 Jan:151:106-107. doi: 10.1016/j.lungcan.2020.11.004. Epub 2020 Nov 13.

Authors

Mingwei Wang¹, Ding Zhang², Guoqiang Wang², Jing Xia², Shiqing Chen², Shuguang Li¹, Yinhua Xu¹, Qianlan Wang¹, Wei Li³

Affiliations

¹ Nantong Third People's Hospital, Nantong, China.
² The Medical Department, 3D Medicines Inc., Shanghai, China.
³ Nantong Third People's Hospital, Nantong, China. Electronic address: [email protected].

PMID: 33309100
DOI: 10.1016/j.lungcan.2020.11.004

No abstract available

Publication types

Letter

MeSH terms

Afatinib / pharmacology
Afatinib / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Drug Resistance, Neoplasm* / drug effects
Drug Resistance, Neoplasm* / genetics
ErbB Receptors* / genetics
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Mutation / drug effects
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use
Quinazolines / therapeutic use

Substances

Protein Kinase Inhibitors
Quinazolines
Afatinib
ErbB Receptors